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Available online at www.sciencedirect.comA significant drop of tissue pH or acidosis is a common feature
of acute neurological conditions such as ischemic stroke, brain
trauma, and epileptic seizures. Acid-sensing ion channels, or
ASICs, are proton-gated cation channels widely expressed in
peripheral sensory neurons and in the neurons of the central
nervous system. Recent studies have demonstrated that
activation of these channels by protons plays an important role
in a variety of physiological and pathological processes such as
nociception, mechanosensation, synaptic plasticity, and
acidosis-mediated neuronal injury. This review provides an
overview of the recent advance in electrophysiological,
pharmacological characterization of ASICs, and their role in
neurological diseases. Therapeutic potential of current
available ASIC inhibitors is discussed.
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Introduction
A stable pH is critical for normal cellular function [1]. In
physiological conditions, extracellular pH (pHo) and
intracellular pH (pHi) are maintained at 7.3 and 7.0
through various H+ transporting mechanisms [1]. In
pathological conditions such as tissue inflammation,
ischemic stroke, neurotrauma, and epileptic seizure,
accumulation of lactic acid because of enhanced
anaerobic glucose metabolism and the release of H+ from
ATP hydrolysis result in marked reduction of tissue pH, a
condition termed acidosis. During severe ischemia, for
example, brain pH can drop to as low as 6.0 [2].
Changes in pHo have profound influence on the physi-
ology of neurons [3], and in pathological conditions affectwww.sciencedirect.comthe outcome of neuronal injury [4]. Mild acidosis, for
example, has been reported to reduce excitatory injury of
neurons [5] because of proton inhibition of NMDA
channels. Severe acidosis, on the other hand, induces
neuronal injury [4,6]. For decades, the entity or receptor
that detects pHo changes surrounding neurons and its
signal transduction pathway remained elusive. The
recent finding that a fall of pHo activates a distinct class
of cation channels, the acid-sensing ion channels (ASICs),
in peripheral sensory neurons and in the neurons of the
central nervous system, dramatically changed the view of
acid signaling and offered new pharmacological targets for
neurological diseases [7,8,9,10–12].
Molecular organization of ASICs
Since the first subunit was cloned 10 years ago [13], six
ASIC subunit proteins, encoded by four genes, have been
identified: ASIC1a, ASIC1b, ASIC2a, ASIC2b, ASIC3,
and ASIC4. All ASICs belong to the degenerin/epithelial
Na+ channel (DEG/ENaC) superfamily, which are Na+-
selective cation channels sensitive to amiloride [13,14].
Though not exclusively, ASICs are highly expressed in
peripheral sensory neurons and in the neurons of the
central nervous system. In the peripheral sensory system,
ASICs are enriched in dorsal root ganglion and trigeminal
ganglion, whereas in the brain, high level of ASICs are
expressed in cerebral cortex, cerebellum, hippocampus,
amygdala, and olfactory bulb [13,15,16].
Based on the biochemical analysis of ENaC [13,17] and
the glycosylation studies of ASIC2a subunits [18], the
proposed membrane topology of each ASIC subunit
consists of two transmembrane domains (TM I and
TM II), linked by a large extracellular cystein-rich loop,
and intracellular N and C termini. Functional ASICs are
believed to be tetrameric assemblies of homomeric or
heteromeric subunits [19] (Figure 1). However, based on
the stoichiometric studies of ENaC, the possibility that
ASICs are assembled with four to nine subunits cannot be
excluded [20,21].
Tissue distribution and electrophysiological
properties of ASICs
Tissue distribution of individual ASICs has been studied
using in situ hybridization, immunohistochemistry, and
electrophysiology, whereas the properties of individual
ASICs have been analyzed largely in herterologous expres-
sion systems and by gene knockout approaches. ASIC1a is
widely expressed in the neurons of peripheral sensory andCurrent Opinion in Pharmacology 2008, 8:25–32
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Figure 1
Proposed tetrameric structure of ASICs. Each channel is assembled
by four identical or different subunits. Each subunit consists of two
transmembrane domain (I and II) linked by large cycteine rich
extracellular domain with intracellular N- and C- termini. For
homomeric ASIC1a channels, activation of the channels by H+
binding induces entry of Na+ and Ca2+ ions.the central nervous system [13,16,22].Homomeric ASIC1a
channels respond to low pHo by mediating a fast and
transient inward current with a threshold pH of 7.0,
and the pH for half maximal activation (pH0.5) at 6.2
[13]. In one study, pH0.5 of 6.8 has been demonstrated [23].
In addition to conducting Na+ ions, homomeric ASIC1a
channels are permeable to Ca2+ ions [10,12,13]. ASIC1b
(ASIC1b) is a splice variant of ASIC1a with restricted
expression in sensory neurons [24]. Homomeric ASIC1b
channels respond to pHo drop with a similar transient
current and a pH0.5 of 5.9 [24,25]. Unlike ASIC1a,
homomeric ASIC1b channels do not show Ca2+ per-
meability. ASIC2a is expressed broadly in peripheral sen-
sory andCNSneurons.Homomeric ASIC2a channels have
a low sensitivity to protons with a pH0.5 of 4.4 [26,27].
ASIC2b is a splice variant of ASIC2a. Though widely
expressed in peripheral sensory and central neurons,
ASIC2b subunits do not form functional homomeric chan-
nels. However, they may associate with other subunits to
form heteromeric ASICs with distinct properties [26].
ASIC3 is predominantly expressed in dorsal root ganglia
[28]. Homomeric ASIC3 channels respond to pHo drops by
a biphasic response with a fast desensitizing current fol-
lowed by a sustained component [28,29]. These channelsCurrent Opinion in Pharmacology 2008, 8:25–32have ahigh sensitivity toprotons andapH0.5 of 6.7hasbeen
reported [29]. ASIC4 subunits show high level of expres-
sion inpituitary gland. Similar toASIC2b, theydonot seem
to form functional homomeric channels [30,31].
Although the exact subunit combination and stoichi-
ometry of ASICs in native neurons remain to be deter-
mined, the relative contributions by ASIC1a, ASIC2a, or
ASIC3 subunit to acid-evoked currents in peripheral
sensory and CNS neurons have been examined
[10,22,23,32]. In medium-sized DRG neurons, for
example, acid-activated currents match those recorded
from heterologous cells expressing a mix of ASIC1,
ASIC2, and ASIC3 subunits [23]. Deletion of any one
subunit did not abolish acid-activated currents, but
altered currents in a manner consistent with heteromul-
timerization of the two remaining subunits, indicating
that combinations of two or more ASIC subunits co-
assemble as heteromultimeric channels in mouse DRG
neurons [23]. In cortical and hippocampal neurons, how-
ever, knockout of ASIC1 gene alone almost completely
eliminated the acid-activated current [10,22,32],
suggesting that ASIC1a is a predominant functional ASIC
subunit in CNS neurons. Further studies suggest that the
acid-activated currents in CNS neurons are largely
mediated by a combination of ASIC1a homomeric chan-
nels and ASIC1a/ASIC2a heteromeric channels [32,33].
ASIC1a is key in establishing the current amplitude.
ASIC2a, on the other hand, has little effect on the
amplitude but influences desensitization, recovery from
desensitization, and pH sensitivity of the channels [32].
Activation of ASICs induces membrane
depolarization and increased intracellular
Ca2+ in neurons
Since all ASICs are Na+-selective channels which have
a reversal potential near Na+ equilibrium potential
(+60 mV), activations of ASICs at normal resting poten-
tials produce exclusively inward currents which result in
membrane depolarization and the excitation of neurons
[33,34]. For homomeric ASIC1a channels, acid activation
also induces Ca2+ entry directly through these channels
[10,12,13]. In addition, the ASIC-mediated membrane
depolarization may facilitate the activation of voltage-
gated Ca2+ channels and NMDA receptor-gated channels
[22], further promoting neuronal excitation and [Ca2+]i
accumulation.
The Ca2+-permeability of ASICs in CNS neurons has
been characterized using fluorescent Ca2+ imaging and
ion-substitution protocols [10,12]. In mouse cortical and
hippocampal neurons, activation of ASICs by decreasing
pHo induces increases of [Ca
2+]i. This acid-induced
increase of [Ca2+]i could be recorded in the presence of
a cocktail blocking other voltage-gated and ligand-gated
Ca2+ channels [10], indicating Ca2+ entry directly through
ASICs. The acid-induced increase of [Ca2+]i is eliminatedwww.sciencedirect.com
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ASIC1 gene knockout [10,12]. Consistent with the find-
ing of fluorescent imaging, acid-activated inward current
is activated when extracellular solution contains Ca2+ as
the only conducting cation [10]. Thus, homomeric
ASIC1a channels constitute an additional and important
Ca2+ entry pathway for neurons.
ASIC1a activation in acidosis-mediated and
ischemic neuronal injury
During ischemia, increased anaerobic glycolysis because
of reduced oxygen supply leads to lactic acid accumu-
lation [2]. Accumulation of lactic acid, alone with
increased H+ release from ATP hydrolysis, causes a
decrease in brain pH, or acidosis. During brain ischemia,
pHo falls to 6.5 or lower [2,35].
Acidosis has long been recognized to play an important
role in ischemic brain injury [36,37]. However, the cel-
lular and molecular mechanism remained unclear. The
widespread expression of ASIC1a in the brain, its acti-
vation by pH drop to the level commonly seen in
ischemic brain, and its demonstrated permeability to
Ca2+ strongly suggested that activation of ASIC1a might
be involved in the pathology of brain injury. Indeed, a
series of recent studies have clearly demonstrated a role
for ASIC1a activation in acidosis-mediated and ischemic
brain injury [10,12,38,39]. In cultured mouse cortical
neurons, activation of ASICs by brief acid incubation
induces glutamate receptor-independent Ca2+-depend-
ent neuronal injury that is inhibited by specific and non-
specific ASIC1a blockade, and by ASIC1 gene knockout
[10]. Reducing [Ca2+]o, which lowers the driving force for
Ca2+ entry through ASICs, also decreases the acid-
induced neuronal injury. Intracerebroventricular injec-
tion of an ASIC1a blocker in rodents reduces the infarct
volume induced by transient or permanent focal ische-
mia by up to 60% [10,39]. Similarly, ASIC1 gene knock-
out produces significant neuroprotection in vivo [10].
The protection by ASIC1a blockade has a time window
of efficacy of up to five hours, and the protection persists
for at least seven days [39]. Attenuating brain acidosis by
intracerebroventricular administration of NaHCO3 is
also protective, further suggesting that acidosis is the
effector of injury.
Since activation of NMDA receptors and subsequent
Ca2+ toxicity has been known to play an important role
in ischemic brain injury, the outcome of co-application of
both blockers has also been investigated. Compared to
ASIC1a or NMDA blockade alone, co-application of
NMDA and ASIC blockade produces additional neuro-
protection, and the presence of ASIC1a blockade pro-
longs the time window of effectiveness of NMDA
blockade [39]. Therefore, Ca2+-permeable ASIC1a
represents a novel pharmacological target for ischemic
brain injury.www.sciencedirect.comASIC activation and epileptic seizure activity
A significant drop of brain pH during intense neuronal
excitation or seizure activity [55–58] suggests that ASIC
activation might play a role in the generation/mainten-
ance of epileptic seizures. In a cell culture model of
epilepsy, brief withdrawal of the NMDA antagonist
kynurenic acid induces a dramatic increase in the firing
of action potentials, in addition to a sustained membrane
depolarization. ASIC blockade by amiloride and the
selective ASIC1a blocker PcTX1 significantly inhibits
the increase of neuronal firing and the sustained mem-
brane depolarization (SY Chang et al., abstract in Soc
Neurosci Abstr 2007, 257.5). In hippocampal slices, high
frequency electrical stimulation or removal of extracellu-
lar Mg2+ triggers spontaneous seizure-like bursting. Bath
perfusion of amiloride and PcTX1 decrease the ampli-
tude and the frequency of these seizure-like bursting
activities. Slices prepared from the brains of ASIC1a
knockout mice demonstrate reduced sensitivity to low
[Mg2+]o-induced or stimulation-evoked seizure activities.
In an in vivo model of epilepsy, intra-amygdala injection
of kainic acid induces sustained polyspike activity
on EEG followed by dramatic injury of CA3 neurons.
In this model, intracerebroventricular injection of PcTX1
reduces both the electrographic seizure activity and the
CA3 neuronal injury (SY Chang et al., abstract in Soc
Neurosci Abstr 2007, 257.5). Together, these data suggest
that activation of ASICs, particularly the ASIC1a chan-
nels, is involved in the generation or maintenance of
seizure activity and resultant seizure-mediated neuronal
injury.
Pharmacological characterization of ASICs
Amiloride
Amiloride, a diuretic agent known to block Na+/H+, Na+/
Ca2+ exchangers and ENaC [40,41], is a non-specific
blocker for ASICs. It reversibly inhibits the ASIC currents
with an IC50 of 10–50 mM [10,13,24,28,42]. Similar to its
effect on the ASIC currents, amiloride inhibits acid-
induced increase of [Ca2+]i and membrane depolarization
[10,12,43,44]. The sustained component of the ASIC3
current, on the other hand, is much less or completely
insensitive to amiloride [28,45]. A recent study has shown
that in cardiac sensory neurons, the small-sustained
ASIC3-like current activated at pH 7.0 is in fact increased
by amiloride [46].
On the basis of the studies of ENaC [47], it is believed
that amiloride inhibits the ASIC current by a direct
blockade of the channel, and that the pre-TM II region
of the channel is critical for its effect. Mutation of Gly-430
in this region, for example, dramatically increases the
sensitivity of ASIC2a current to amiloride [48].
Therapeutic potential
In peripheral sensory system, amiloride has been shown
to suppress acid-induced pain [49–52], whereas in CNSCurrent Opinion in Pharmacology 2008, 8:25–32
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Figure 3neurons, it reduces acid-mediated and ischemic neuronal
injury [10,12]. However, because of its nonspecificity for
various ion channels and ion exchange systems, it has low
potential to be used as a future analgesic or neuroprotec-
tive agent in human subjects. In a lower or similar
concentration range to that inhibits ASICs, amiloride also
blocks other ion channels (e.g. ENaC, T-type Ca2+ chan-
nels) and ion exchange systems (Na+/H+, Na+/Ca2+
exchanger). Recent studies have suggested that the nor-
mal activity of Na+/Ca2+ exchanger, for example, is critical
for maintaining cellular Ca2+ homeostasis and the survival
of neurons against delayed calcium deregulation and
injury caused by glutamate receptor activation [53]. Con-
versely, inhibition of Na+/Ca2+ exchanger by amiloride is
expected to compromise normal neuronal Ca2+ handling,
which may transform the Ca2+ transient elicited by non-
toxic glutamate concentrations into a lethal Ca2+ over-
load. The inhibition of Na+/Ca2+ exchanger by amiloride
may partially explain its reduced neuroprotective efficacy
in vivo compared with the ASIC1a-specific blocker
PcTX1 [10]. It may also explain the finding that pro-
longed incubation with amiloride (e.g. 5 h) itself induces
injury of cultured mouse cortical neurons [10]. Although
amiloride itself is unlikely to be used as a neuroprotective
agent for neurological conditions, one direction for
future drug development could be to chemically modify
the structure of amiloride (Figure 2) to achieve amolecule
that specifically blocks ASICs, or at least has more selec-
tivity for these channels.
A-317567
A-317567, a small molecule unrelated to amiloride
(Figure 2), is a new non-selective ASIC blocker [52]. It
inhibits the ASIC1a-like, ASIC2a-like, and ASIC3-like
currents in rat DRG neurons with IC50 of 2–30 mM.
Unlike amiloride, A-317567 blocks both the fast and
the sustained components of the ASIC3-like currents.
In a rat thermal hyperalgesia model, A-317567 is fully
efficacious at a dose 10-fold lower than amiloride. It is also
effective in a skin incision model of post-operative pain.
A-317567 does not show diuresis or natriuresis activity
[52], suggesting that it is more specific for ASICs than
amiloride.Figure 2
Chemical structure of amiloride and A-317567.
Current Opinion in Pharmacology 2008, 8:25–32Therapeutic potential
Compared with amiloride, A-317567 appears to have
better potential to be established as a future analgesic
agent. Its inhibition of sustained ASIC3 current suggests
that it might be useful in suppressing acidosis-mediated
chronic pain. Currently, it is unknown whether A-317567
is also an effective neuroprotective agent. Future study
would be helpful to demonstrate whether it is efficient in
reducing acidosis-induced neuronal injury in cell culture
models and infarct volume in animal models of ischemia.
When applied peripherally, A-317567 shows minimal
brain penetration in normal conditions [52]. It would
be interesting to know whether it can reach the brain
in pathological conditions (e.g. ischemia) where blood-
brain-barrier may have been compromised. Additional
studies may be helpful to elucidate the mechanism
underlying A-317567 inhibition of ASIC activity and
the binding site(s) where it interacts with the channels.
It is also important to know whether A-317567 affects the
activities of other ion channels and ion exchanger sys-
tems.
PcTX1
Psalmotoxin 1 (PcTX1) is a peptide toxin that specifically
inhibits the ASIC1a current [54]. It was isolated from the
venomofSouthAmerican tarantulaPsalmopoeusCambridge.
The toxin contains 40 amino acids cross-linked by three
disulfide bridges (Figure 3). In heterologous expression
systems, PcTX1 potently and specifically inhibits the acid-
activated current mediated by homomeric ASIC1a sub-
units in a nanomolar concentration range (IC50 < 1 nM),
without affecting the currents mediated by other configur-
ations of ASICs [54]. At concentrations that effectively
inhibit the ASIC1a current, it has no effect on voltage-
gatedNa+, K+, Ca2+ channels, nor an effect on several other
ligand-gated ion channels [10]. Thus, PcTX1 is so far the
best-known specific blocker for ASICs and an indispen-
sable pharmacological tool for the studies of ASIC1a-
mediated processes [10,54–56].Amino acid sequence and disulfide linkage for PcTX1 and APETx2.
www.sciencedirect.com
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acts as a gating modifier. It shifts the channel from its
resting towards the inactivated state through an increase
of its apparent affinity for protons [57]. Interestingly, this
PcTX1-induced shift of the pH-dependent inactivation
of ASIC1a is Ca2+-dependent, where increasing extra-
cellular Ca2+ results in a decrease of the PcTX1 inhibition
[57]. This finding implies that, in neurological conditions
(e.g. brain ischemia) where a significant drop of extra-
cellular Ca2+ concentration occurs [58,59], the potency for
PcTX1 inhibition of the ASIC1a channels would increase.
The binding site for PcTx1 has recently been analyzed
using radiolabelled tools [60]. It binds principally on
cysteine-rich domains I and II (CRDI and CRDII) of
the extracellular loop. Although the post-transmembrane
domain I and pre-transmembrane domain II regions are
not involved in the binding, they are crucial for the ability
of PcTx1 to inhibit the ASIC1a current [60].
Therapeutic potential
Targeting Ca2+ permeable ASIC1a by intracerebroven-
tricular administration of PcTX1 has been demonstrated
to be effective in reducing ischemic brain injury in rat andFigure 4
Simplified diagram demonstrating the role of ASIC1a activation in ischemic
Upper left panel represents neurons in ischemic conditions where the conc
the channels resulting in large influx of Na+ and Ca2+ ions. Overloading neu
the brain (upper right panel). Lower left panel represents neurons in ischem
Na+ and Ca2+ ions are reduced because of a direct blockade of the channe
resulting in neuroprotection and small infarct volume (lower right panel).
www.sciencedirect.commouse models of ischemia [10,39]. A preliminary study
also suggested that blocking these channels is effective in
suppressing epileptic seizure activity and seizure-
induced neuronal injury (SY Chang et al., abstract in
Soc Neurosci Abstr 2007, 257.5). In mouse models of focal
ischemia, it was demonstrated that blocking ASIC1a by
PcTX1 has a neuroprotective time window of 5h [39].
These findings suggest that a specific ASIC1a blocker is
useful as a neuroprotective agent for various neurological
diseases (Figure 4). However, as discussed below, PcTX1
itself may not be an ideal pharmacological agent for
human subject: (1) PcTX1 consists of 40 amino acids
linked by three disulfide bonds. Synthesis of this toxin
in a large quantity might be a challenge for pharmaceu-
tical companies. (2) Because of the presence of three
disulfide bonds, which are subjected to modification by
oxidizing/reducing conditions, the long-term stability of
the toxin could be an issue. (3) The large molecule of this
toxin (5 kD) makes it difficult to across the blood–brain
barrier (BBB) thus preventing its use by conventional
routine of administration (e.g. i.v. or i.p.). Indeed, it has
not been demonstrated in animal studies that a peripheral
administration of this toxin (i.v.) is sufficient to reduce
ischemic brain injury [39]. Future efforts may considerneuronal injury and the neuroprotection by ASIC1a blocker/inhibitor.
entration of extracellullar protons is high. Binding of protons opens
rons with Ca2+ induces neuronal injury and large infarct volume of
ic conditions but in the presence of ASIC blocker or inhibitor. Influx of
l (e.g. by amiloride) or an alteration of channel gating (e.g. by PcTX1),
Current Opinion in Pharmacology 2008, 8:25–32
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BBB, have long-term stability, but still block the ASIC1a
channels. Additional efforts should focus on the search for
new small molecules that specifically blocks the ASIC1a
channels. Since activation of ASIC1a is also involved in
the processes of learning, memory and fear [22,56], pro-
longed blockade of these channels in patients may induce
some behavior changes.
APETx2
APETx2 is a 42 amino-acid peptide toxin isolated from
sea anemone Anthopleura elegantissima. It is a potent
and selective inhibitor for homomeric ASIC3 and ASIC3
containing channels [61]. It reduces transient peak acid-
evoked currents mediated by homomeric ASIC3 channels
in heterologous expression systems and in primary cul-
tures of sensory neurons [61]. In contrast to the peak
ASIC3 current, the sustained component of the ASIC3
current is insensitive to APETx2. In addition to homo-
meric ASIC3 channels (IC50 = 63 nM for rat and 175 nM
for human), APETx2 inhibits heteromeric ASIC3/1a
(IC50 = 2 mM), ASIC3/1b (IC50 = 900 nM), and ASIC3/
2b (IC50 = 117 nM). Homomeric ASIC1a, ASIC1b,
ASIC2a, and heteromeric ASIC3/2a channels, on the
other hand, are not sensitive to APETx2. Similar to
PcTX1, APETx2 is cross-linked by three disulfide bonds
(Figure 3) [61]. However, it does not show any sequence
homologies with PcTX1. At present, the mode of action
for APETx2 is still unknown.
Therapeutic potential
Since activation of ASIC3 has been implicated in various
pain processes [46,51,62,63], APETx2 may be a useful
analgesic agent in the treatment or prevention of pain in
peripheral sensory system. However, its lack of inhibition
of sustained ASIC3 current suggests that it may not be
effective in suppressing the chronic pain stimuli. It is also
unknown whether it inhibits inflammation-induced
increased expression of ASICs. The lack of inhibition of
ASIC expression, and likely the COXs activity, would
suggest that APETx2 will not be as effective as NSAIDs
(see below) in suppressing the pain by tissue inflammation.
Non-steroid anti-inflammatory drugs
Non-steroid anti-inflammatory drugs (NSAIDs) are the
most commonly used anti-inflammatory and analgesic
agents. The well accepted mechanism for the effect of
NSAIDs is the inhibition of the synthesis of prostaglan-
dins (PGs), a main tissue inflammatory substance. How-
ever, exceptions to the correlation of PG synthetase
inhibition with anti-inflammatory activity have been
noted, suggesting additional mechanism(s) may be
involved. A recent study demonstrated that various
NSAIDs also inhibit the activity of ASICs at therapeutic
doses for analgesic effects [64]. Ibuprofen and flurbipro-
fen, for example, inhibit ASIC1a containing channels
with an IC50 of 350 mM. Aspirin and salicylate inhibitCurrent Opinion in Pharmacology 2008, 8:25–32ASIC3 containing channels with an IC50 of 260 mM,
whereas diclofenac inhibits the same channels with an
IC50 of only 92 mM. In addition to a direct inhibition of
the ASIC activity, NSAIDs also prevent inflammation
induced increase of ASIC expression in sensory neurons
[64].
Therapeutic potential
Tissue acidosis is a common feature of many painful
states. During tissue inflammation, ischemia, and infec-
tion, or in tumors, hematomas, and blisters, pHo can drop
from 7.4 to as low as 5.0 [65,66]. The combined inhibition
of NSAIDs on PG synthesis, ASIC currents, and ASIC
expression make them ideal for a large spectrum of pain
conditions, particularly the pain caused by tissue inflam-
mation. In the acute phase of tissue inflammation, for
example, the rapid inhibition of ASIC currents by
NSAIDs blocks the activation of pain-sensing neurons
by inflammatory acidosis. Later, the NSAIDs suppress
the inflammation and pain by their effect on COXs,
limiting the production of prostaglandins. In the chronic
phase, they may reduce the sensitization to pain by
combined inhibition of COXs, ASIC currents, and ASIC
expression.
Concluding remarks
ASICs represent new biological components and thera-
peutic targets in peripheral sensory and CNS neurons.
Increasing evidence supports the involvement of ASIC
activation in physiological processes such as synaptic
plasticity, and in neurological diseases such as brain
ischemia and epileptic seizures. On-going studies are
expected to identify the involvement of ASIC activation
or changes in ASIC expression in other physiological
processes and neurological disorders. Future develop-
ment of potent and specific blockers for individual ASIC
subunits will dramatically advance our understanding of
the role of these channels in physiological and pathologi-
cal processes, and for establishing novel therapeutic strat-
egies for neurological diseases. In addition to channel
blockers/inhibitors discussed here, alternative thera-
peutic strategies may consider targeting endogenous sig-
naling molecules/proteins, which closely modulate the
activities of ASICs [67], for example, a kinase-anchoring
protein 150 [68].
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